Previous close | 0.1300 |
Open | 0.1350 |
Bid | 0.1300 x 42183000 |
Ask | 0.1350 x 20752900 |
Day's range | 0.1300 - 0.1350 |
52-week range | 0.0400 - 0.1750 |
Volume | |
Avg. volume | 3,817,424 |
Market cap | 111.761M |
Beta (5Y monthly) | 0.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0090 |
Earnings date | 25 Aug 2022 - 29 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ResApp Health Limited (ASX:RAP) today announced positive results for a new novel cough audio-based COVID-19 screening test that only requires a smartphone. In an exploratory clinical trial of 741 patients (446 COVID-19 positive) recruited in the United States and India, ResApp's screening test, which uses machine learning to analyse the sound of a patient's cough, was found to correctly detect COVID-19 in 92% of people with the infection.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...